Q-omics provides the consensus-scored CDC14C profile across patient tissues and cancer cell-line models. CDC14C expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, CDC14C is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, CDC14C RNA expression shows 10,229 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, BRCA, and THYM as cancer lineages where CDC14C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC14C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC14C survival associations across molecular data types. CDC14C RNA expression shows survival associations in the most cancer types (17), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC14C RNA expression–survival associations across cancer types. High CDC14C expression shows unfavorable associations in CESC, THCA, READ and LUAD, but favorable associations in COAD and SKCM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify CESC as the clearest survival context for CDC14C RNA expression.
This table summarizes CDC14C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CDC14C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC14C shows lower tumor expression in BRCA, THCA, PAAD and KIRC and higher tumor expression in KIRP and HNSC. The BRCA box plot shows higher CDC14C RNA expression in normal versus tumor tissue (log2 FC = −0.032, t-test p < 0.001).
This table shows molecular features associated with CDC14C in patient tissues and cancer cell lines. In patient samples, CDC14C shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC14C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
